London
· Delayed Price · Currency is GBP · Price in GBX Hemogenyx Pharmaceuticals Statistics
Total Valuation
LON:HEMO has a market cap or net worth of GBP 7.43 million. The enterprise value is 9.85 million.
| Market Cap | 7.43M |
| Enterprise Value | 9.85M |
Important Dates
The last earnings date was Friday, April 25, 2025.
| Earnings Date | Apr 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LON:HEMO has 4.09 million shares outstanding. The number of shares has increased by 16.95% in one year.
| Current Share Class | 4.09M |
| Shares Outstanding | 4.09M |
| Shares Change (YoY) | +16.95% |
| Shares Change (QoQ) | +15.27% |
| Owned by Insiders (%) | 7.43% |
| Owned by Institutions (%) | 65.73% |
| Float | 3.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 8.71 |
| P/TBV Ratio | 17.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.75 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.37 |
Financial Position
The company has a current ratio of 0.72, with a Debt / Equity ratio of 3.07.
| Current Ratio | 0.72 |
| Quick Ratio | 0.14 |
| Debt / Equity | 3.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.63 |
| Interest Coverage | -19.80 |
Financial Efficiency
Return on equity (ROE) is -309.56% and return on invested capital (ROIC) is -73.03%.
| Return on Equity (ROE) | -309.56% |
| Return on Assets (ROA) | -65.15% |
| Return on Invested Capital (ROIC) | -73.03% |
| Return on Capital Employed (ROCE) | -176.13% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -351,199 |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.54% in the last 52 weeks. The beta is 0.57, so LON:HEMO's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -70.54% |
| 50-Day Moving Average | 205.01 |
| 200-Day Moving Average | 405.40 |
| Relative Strength Index (RSI) | 40.83 |
| Average Volume (20 Days) | 21,539 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.38M |
| Pretax Income | -5.63M |
| Net Income | -5.62M |
| EBITDA | -5.15M |
| EBIT | -5.38M |
| Earnings Per Share (EPS) | -1.70 |
Balance Sheet
The company has 159,265 in cash and 2.62 million in debt, giving a net cash position of -2.46 million or -0.60 per share.
| Cash & Cash Equivalents | 159,265 |
| Total Debt | 2.62M |
| Net Cash | -2.46M |
| Net Cash Per Share | -0.60 |
| Equity (Book Value) | 853,494 |
| Book Value Per Share | 0.26 |
| Working Capital | -319,605 |
Cash Flow
In the last 12 months, operating cash flow was -4.14 million and capital expenditures -13,285, giving a free cash flow of -4.15 million.
| Operating Cash Flow | -4.14M |
| Capital Expenditures | -13,285 |
| Free Cash Flow | -4.15M |
| FCF Per Share | -1.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LON:HEMO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.95% |
| Shareholder Yield | -16.95% |
| Earnings Yield | -75.63% |
| FCF Yield | -55.90% |
Stock Splits
The last stock split was on December 13, 2024. It was a reverse split with a ratio of 0.0025.
| Last Split Date | Dec 13, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0025 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |